FLINT, Mich., May 23, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), has partnered with SMRxT Inc. to begin deploying its Nomi™ medication adherence system.
Nomi is a real-time, data-driven solution that helps health care professionals understand and manage patients' adherence challenges.
The system captures data about how patients take medication and translates it into actionable information for clinical interventions and better patient engagement.
"One of the largest health care problems is medication nonadherence," said Gary Rice, Diplomat executive vice president of operations. "Nomi empowers patients, guides them to healthy behavior, and prevents unnecessary health care costs. With Nomi, we can provide immediate clinical interventions and help prevent failed therapy."
When a patient takes their medication, sensor technologies record the time and the number of tablets taken. That data is posted to the patient's adherence record and made available to health care providers through a secure website.
With this technology, pharmacies know a patient's precise dosing behavior and can contact them right away to resolve adherence barriers, such as side effects that deter them from continuing therapy.
"We are excited to partner with Diplomat on this new strategic initiative," said Michael Huffer, RPh, president and CEO of SMRxT. "By joining forces, we will bring a novel adherence and persistency program to market. We're looking forward to helping Diplomat patients achieve higher medication adherence and better health outcomes."
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended Dec. 31, 2016, and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) is the nation's largest independent provider of specialty pharmacy services—helping patients and providers in all 50 states. The company offers medication management programs for people with complex chronic diseases and delivers unique solutions for manufacturers, hospitals, payors, providers, and more. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information, visit diplomat.is.
Nomi™, a product of SMRxT®, is a medication adherence system that uses real-time data and communications to improve patient outcomes. Nomi accurately captures multiple medication data points from patients, in real-time, to monitor how and when they take their medication. The system then translates patient behavior into actionable information for patient interventions and engagement. Nomi's Engagement Engine can communicate to the patient, family and care teams to help improve patient behavior without the patient lifting a finger. For more information, visit NomiAdherence.com.